BioCentury
ARTICLE | Clinical News

Merck's Zerbaxa non-inferior to meropenem in Phase III for bacterial pneumonia

September 14, 2018 1:06 PM UTC

Merck & Co. Inc. (NYSE:MRK) said Zerbaxa ceftolozane/tazobactam met the primary endpoints in the Phase III ASPECT-NP trial to treat hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP). Zerbaxa was non-inferior to meropenem in all-cause mortality at day 28 and in clinical cure rate at the test-of-cure (TOC) visit 7-14 days after the end of treatment.

The double-blind ASPECT-NP trial enrolled 726 adult patients with ventilated HABP or VABP requiring IV antibiotic therapy to receive 3 g IV Zerbaxa or 1 g IV meropenem every eight hours for 8-14 days, or for 14 days in patients with Pseudomonas aeruginosa infection...

BCIQ Target Profiles

AmpC beta lactamase